Mainz Biomed and Thermo Fisher Scientific, through its subsidiary Life Technologies, announced an agreement to jointly develop and potentially commercialize Mainz Biomed's next-generation colorectal cancer (CRC) screening test.
Financial and other terms of the agreement were not disclosed.
In a statement, the companies said that Mainz Biomed will use Thermo Fisher's technologies, instrumentation, and information translation systems to develop proprietary assays for its mRNA-based next-generation CRC screening tests.
Mainz Biomed's noninvasive, stool-based ColoAlert test is designed to not only detect CRC early, but it also focuses on detecting precancerous lesions, particularly advanced adenomas; it has demonstrated good results in clinical trials in both the U.S. and European Union, the firms said.
